Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.68 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.68 |
| ▸ | TERT | O14746 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 5/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | P4HB | P07237 | 1/20 | 0.56 |
| ▸ | NQO2 | P16083 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31436356 | 1.00 | CYP1B1 (0.68) | CYP1B1CYP1A1TERTMAOBNR1H4 | |
| SCHEMBL30736439 | 0.85 | TERT (0.70) | TERTMAOBNR1H4ALDH1A1MAOA | |
| SCHEMBL31436349 | 0.85 | TERT (0.70) | TERTMAOBNR1H4ALDH1A1MAOA | |
| SCHEMBL2541146 | 0.85 | TERT (0.70) | TERTMAOBNR1H4ALDH1A1MAOA | |
| SCHEMBL2541144 | 0.85 | TERT (0.70) | TERTMAOBNR1H4ALDH1A1MAOA | |
| SCHEMBL31436362 | 0.83 | TERT (0.67) | TERTMAOBNR1H4ALDH1A1MAOA | |
| SCHEMBL9702240 | 0.83 | CYP3A4 (0.71) | CYP1B1CYP1A1MAOBNR1H4P4HB | |
| SCHEMBL9702245 | 0.83 | CYP3A4 (0.71) | CYP1B1CYP1A1MAOBNR1H4P4HB | |
| SCHEMBL30736468 | 0.83 | TERT (0.67) | TERTMAOBNR1H4ALDH1A1MAOA | |
| SCHEMBL4953081 | 0.83 | GUSB (0.71) | CYP1B1CYP1A1MAOBNR1H4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228795-A1 | ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. | 2025-07-17 | — | — | US | disclosed |
| EP-4561560-A1 | ESTROGENIC COMPOUNDS AND METHODS OF USE | Iaterion, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119677514-A | Estrogenic compounds and methods of use | 益特瑞恩公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2024026034-A1 | ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228795-A1 | ESTROGENIC COMPOUNDS AND METHODS OF USE | ESR1, ESR2, CYP19A1 | CYP1B1 158/4885CYP1A1 121/4885TERT 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.